Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod alpha + pembrolizumab in head and neck squamous cell carcinoma
NCT04811027Phase 2Completed
- Sponsor
- Immutep Limited
- Start
- Aug 2021
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 2 trial of eftilagimod alpha in head and neck squamous cell carcinoma (HNSCC), sponsored by Immutep Limited. Started Aug 2021; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04811027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811027.